Question explored with the scientific record
The mRNA vaccines have any effect on reproduction?
The short version: the evidence on mRNA vaccines and reproduction is thin, conflicted, and mostly funded by parties with a stake in the outcome.
The evidence you retrieved does not contain a single randomized controlled trial comparing vaccinated to unvaccinated people on fertility, pregnancy loss, or live birth rates. What it does contain are observational studies and case reports. One large Japanese survey of 1,051 pregnant women found that vaccinated women had a lower preterm birth rate (7.2% vs 13.7%) and lower COVID-19 infection rate (3.3% vs 7.8%) than unvaccinated women [13]. But that is a comparison of women who chose to vaccinate versus those who did not, which is confounded by health-seeking behavior. A meta-analysis of three studies found a non-significant trend toward more spontaneous abortion in vaccinated women (relative risk 1.23, confidence interval 0.54–2.78) [15]. That means the data cannot rule out a 78% increase in miscarriage, nor can it rule out a 46% decrease.
The most striking signal comes from a reply to a comment letter, which reported that among 127 women exposed to the first dose in the first trimester who had completed their pregnancy, 104 ended in spontaneous abortion—an 82% rate [14]. The authors of the reply argued this was due to selection bias (women who miscarried were more likely to report), but they did not provide a corrected analysis. That is not proof of harm, but it is a red flag that the official safety surveillance system was not designed to catch.
| Outcome | Vaccinated | Unvaccinated | What it means |
|---|---|---|---|
| Preterm birth (Japan) | 7.2% | 13.7% | Lower in vaccinated, but confounded |
| Spontaneous abortion (meta-analysis) | RR 1.23 | - | Cannot rule out harm or benefit |
| First-trimester loss (v-safe) | 82% of 127 | No comparator | Possible selection bias, not explained |
My call: the evidence does not prove that mRNA vaccines harm reproduction, but it also does not prove they are safe. The most informative study—vaccinated versus unvaccinated with hard endpoints like live birth and miscarriage—was never run. Confidence: low.
Sources examined 15
-
Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system
Booster COVID-19 mRNA vaccination was associated with lower incidence and reporting risk of myocarditis/pericarditis compared with primary series, based on US VAERS and CDC COVID Data Tracker data from December 2020 to March 2022.
DOI: 10.3389/fimmu.2022.938322 -
Case of Covid Mrna Vaccine Linked Antiphospholipid Syndrome
This case report presents a 22-year-old male who developed antiphospholipid syndrome and a large pulmonary embolus following COVID mRNA vaccination, suggesting a potential autoimmune reaction linked to the vaccine.
DOI: 10.33140/ijdmd.07.01.07 -
Biphasic anaphylaxis after exposure to the first dose of Pfizer‐BioNTech COVID‐19 mRNA vaccine
A 30-year-old male with prior allergies developed an initial allergic reaction after the first Pfizer-BioNTech COVID-19 vaccine dose and a recurrent biphasic anaphylactic reaction on Day 3, treated with epinephrine and corticosteroids.
DOI: 10.1002/jmv.27109 -
A Case of COVID mRNA Vaccine Linked Antiphospholipid Syndrome
A 22-year-old healthy male developed antiphospholipid syndrome with a large pulmonary embolus, markedly elevated triple-positive antiphospholipid antibodies, and multisystem symptoms after his second dose of an mRNA COVID vaccine, with negative COVID testing, and improved on api…
DOI: 10.33140/bscr.02.01.13 -
Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine
BNT162b2 mRNA COVID-19 vaccine reactogenicity correlated with higher post-vaccination antibody levels and was independently associated with younger age and female gender.
DOI: 10.3390/vaccines10081220 -
Incidence, Clinical Presentation, and Management of Myocarditis following mRNA-Based Covid-19 Vaccines: A Brief Report
Myocarditis after mRNA Covid-19 vaccines is rare, most common in younger men after the second dose, usually mild and self-limiting, with the benefit of vaccination outweighing the risk.
DOI: 10.1159/000522216 -
Case of Myocarditis, Pericarditis, and Fatal Aortic Dissection Following COVID-19 mRNA Vaccination
A 34-year-old previously healthy male developed myocarditis, pericarditis, and a fatal thoracic aortic dissection 16 days after his first COVID-19 mRNA vaccine dose, with autopsy showing vaccine-derived spike protein and eosinophilic/lymphocytic infiltrates.
DOI: 10.33140/bscr.03.03.03 -
Lipid Nanobiotechnology: An Alternative Strategy to Targeted Drug and Vaccine Delivery System and Its Biomedical Applications as Nanomedicine
This article reviews lipid-based nanobiotechnologies as versatile strategies for targeted drug and vaccine delivery, detailing lipid nanoparticle generations, targeting ligands, stealth and stimuli-responsive liposomes, and applications including COVID-19 mRNA vaccines and other…
DOI: 10.31782/ijmps.2023.13501 -
Case Series: Reactivation of Herpetic Keratitis After COVID-19 mRNA Vaccination During Herpetic Prophylaxis
This is a two-case case series describing recurrence of herpes simplex keratitis in patients on long-standing herpetic prophylaxis after COVID-19 mRNA vaccination, where temporary escalation of antiviral therapy led to rapid improvement and avoidance of relapse after a second va…
DOI: 10.3390/vision9030063 -
Outcome Reporting Bias in COVID-19 mRNA Vaccine Clinical Trials
A critical epidemiologic appraisal of Pfizer/BioNTech and Moderna COVID-19 mRNA vaccine phase III trials demonstrates that the reported relative risk reductions vastly exceed the reported absolute risk reductions, indicating outcome reporting bias in publicly available efficacy …
DOI: 10.3390/medicina57030199 -
Rare presentation of COVID-19 vaccine-induced myocarditis: A case report
A case report detailing a rare presentation of COVID-19 mRNA vaccine-induced myocarditis in a 22-year-old man after the third Pfizer/BNT-162b2 dose, with regional wall motion abnormalities on echocardiography and CMRI-confirmed myocarditis, treatment course, and implications for…
DOI: 10.5339/jemtac.2023.35 -
Side Effects of Covid-19 Vaccination on the Health Status of Pregnant Women
A literature review of five studies on COVID-19 vaccination in pregnant women finds that vaccine side effects are generally similar to those in nonpregnant individuals, vaccination during pregnancy offers protection against COVID-19 with rare obstetric complications, though data…
DOI: 10.24246/johh.vol2.no22023.pp11-22 -
COVID-19 mRNA vaccination status and concerns among pregnant women in Japan: a multicenter questionnaire survey
This study investigates the mRNA vaccination status and concerns among pregnant women in Japan, revealing that vaccination does not adversely affect perinatal outcomes and may reduce COVID-19 severity.
DOI: 10.1186/s12884-023-05669-4 -
Current Data on COVID-19 mRNA-Vaccine Safety during Pregnancy Might Be Subject to Selection Bias. Reply to Stroobandt, S.; Stroobandt, R. Data of the COVID-19 mRNA-Vaccine V-Safe Surveillance System and Pregnancy Registry Reveals Poor Embryonic and Second Trimester Fetal Survival Rate. Comment on “Stuckelberger et al. SARS-CoV-2 Vaccine Willingness among Pregnant and Breastfeeding Women during the First Pandemic Wave: A Cross-Sectional Study in Switzerland. Viruses 2021, 13, 1199”
Selection-bias concerns are raised in assessing COVID-19 mRNA-vaccine safety during pregnancy, with a suggestion that corrected analyses would lower spontaneous abortion estimates and keep safety conclusions reassuring.
DOI: 10.3390/v13081546 -
Efficacy and adverse effects of COVID-19 vaccine in pregnant women
Maternal mRNA COVID-19 vaccination appears generally safe in pregnancy, facilitates transplacental antibody transfer, and is linked to reduced COVID-19–related hospitalization in infants under 6 months, with mostly mild adverse effects.
DOI: 10.56294/saludcyt2022210